0001493152-23-017789.txt : 20230516 0001493152-23-017789.hdr.sgml : 20230516 20230516161557 ACCESSION NUMBER: 0001493152-23-017789 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230512 FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BERMAN MICHAEL CENTRAL INDEX KEY: 0001186801 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35731 FILM NUMBER: 23927705 MAIL ADDRESS: STREET 1: 735 PALAMAR AVENUE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: InspireMD, Inc. CENTRAL INDEX KEY: 0001433607 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 262123838 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 BUSINESS PHONE: (888) 776-6804 MAIL ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 FORMER COMPANY: FORMER CONFORMED NAME: Saguaro Resources, Inc. DATE OF NAME CHANGE: 20080428 4 1 ownership.xml X0407 4 2023-05-12 0 0001433607 InspireMD, Inc. NSPR 0001186801 BERMAN MICHAEL C/O INSPIREMD, INC. 4 MENORAT HAMAOR ST. TEL AVIV L3 6744832 ISRAEL 1 0 0 0 0 Common Stock 2023-05-12 4 P 0 122497 1.6327 A 122497 I See footnote Common Stock 42827 D Series H Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 61249 1.6327 A 2023-05-15 Common Stock 61249 61249 I See footnote Series I Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 61248 1.6327 A 2023-05-15 Common Stock 61248 61248 I See footnote Series J Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 61249 1.6327 A 2023-05-15 Common Stock 61249 61249 I See footnote Series K Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 61248 1.6327 A 2023-05-15 Common Stock 61248 61248 I See footnote The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement"). The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. These securities are held by the Michael Berman Revocable Trust. The aggregate number of warrants reported in this row consists of 61,249 Series H Warrants that were acquired in the Private Placement. The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial. The aggregate number of warrants reported in this row consists of 61,248 Series I Warrants that were acquired in the Private Placement. The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm). The aggregate number of warrants reported in this row consists of 61,249 Series J Warrants that were acquired in the Private Placement. The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm. The aggregate number of warrants reported in this row consists of 61,249 Series K Warrants that were acquired in the Private Placement. The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. /s/ Craig Shore, Attorney-in-Fact for Michael Berman 2023-05-16